Tandem Diabetes Care (TNDM) has an average rating of overweight and mean price target of $29.08, according to analysts polled by FactSet.
What else is happening in Research?
Research
Craig Hallum Downgrades Apogee Therapeutics to Hold From Buy, $135.11 Price Target
Apogee Therapeutics (APGE) has an average rating of overweight and mean price target of $122.86, according to analysts polled by FactSet.Price: $132.63, Change: $+42.25, Percent Change: +46.75%
$APGE
Research
Citigroup Downgrades Apogee Therapeutics to Neutral From Buy, Price Target is $135
Apogee Therapeutics (APGE) has an average rating of overweight and mean price target of $119.07, according to analysts polled by FactSet.Price: $132.65, Change: $+42.27, Percent Change: +46.76%
$APGE
Research
Update: Seaport Global Upgrades BWX Technologies to Buy From Neutral, Price Target is $245
(Updates with the analyst's commentary.)Seaport Global upgraded BWX Technologies (BWXT) to buy from neutral, citing the company's acquisition of Precision Components Group after a "strong" fiscal Q1.PCG 2025 revenue was about $125 million and it paid about $200 million for the firm, the brokerage said, citing BWX management.PCG is an authorized nuclear component manufacturer and certified for aerospace and defense quality-management, Seaport said.BWX Technologies has an average rating of overweight and mean price target of $240.17, according to analysts polled by FactSet.Price: $212.56, Change: $+7.16, Percent Change: +3.49%
$BWXT